Pharmacological treatment of acute renal failure in intensive care unit patients

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 161-173

  Moreau, Delphine ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

URATE OXIDASE;

ACUTE KIDNEY FAILURE; HUMAN; HYPERURICEMIA; INTENSIVE CARE UNIT; METABOLISM; PROGNOSIS; REVIEW; TUMOR LYSIS SYNDROME;

HUMANS; HYPERURICEMIA; INTENSIVE CARE UNITS; KIDNEY FAILURE, ACUTE; PROGNOSIS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 16644370769     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (67)

1. Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94:133-139.
2. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT: Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 1981;60:218-229.
3. Stapelton FB, Strother DR, Roy S, Wyatt RJ, McKay CP, Murphy SB: Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988;82:863-869.
4. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL: Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68:486-491.
5. Griffin TC, Bowman WP, Winick NJ, Buchanan GR: Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood: Further experience with total therapy B. Med Pediatr Oncol 1994;23:393-399.
6. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al: Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002;13:789-795.
7. Patte C, Oya S, Sommelet D: European experience in the treatment of hyperuricemia. Semin Hematol 2001;38(suppl 10):9-12.
8. Atra A, Gerrard M, Hobson R, et al: Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - Results of the UKCCSG 9003 protocol. Br J Cancer 1998;77:2281-2285.
9. Bowman WP, Shuster JJ, Cook B, et al: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV noncleaved-cell lymphoma: A pediatric oncology group study. J Clin Oncol 1996;14:1252-1261.
10. Aubert JD, Claeys M, Zwahlen A, Wauters JP: Hyperphosphatemie et insuffisance rénale transitoire après chimiothérapie d'une leucémie lymphoblastique aigue. Schweiz Med Wochenschr 1988;118:1953-1956.
11. Boles JM, Dutel JL, Brière J, Mialon P, Robasckiewicz M, Garre M, Brière J: Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984;53:2425-2429.
12. Monballyu J, Zachee P, Verberckmoes R, Bongaerts MA: Transient acute renal failure due to tumor lysis induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 1984;22:47-50.
13. Maierhofer WJ: Renal disease from excess uric acid. Postgrad Med 1987;82:123-130.
14. Conger JD: Acute uric acid nephropathy. Med Clin North Am 1990;74:859-871.
15. Kelton J, Kelley WN, Holmes EW: A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med 1978;138:612-615.
16. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, et al: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001;71:900-905.
17. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
18. Watanabe S, Kanellis J, Nakagawa T, Han L, Ohashi R, Lan H, et al: Reducing uric acid as a means to prevent cardiovascular and renal disease. Expert Opin Ther Patents 2002;12:1-7.
19. Rozenberg S, Koeger AC, Bourgeois P: Urate oxidase for gouty arthritis in cardiac transplant recipients. J Rheumatol 1993;20:2171.
20. Rozenberg S, Roche B, Dorent R: Urate oxidase for the treatment of tophaceous gout in heart transplant recipients: A report of three cases. Rev Rhum Engl Ed 1995;62:392-394.
21. Ippoliti G, Negri M, Abelli P, Martinelli I, Minzioni G, Vigano M: Urate oxidase in severe hyperuricemia during acute renal failure after heart transplantation. Haematologica 1990;75:487-488.
22. Day RO, Birkett DJ, Jicks M, Miners JO, Graham GG, Brooks PM: New uses of allopurinol. Drugs 1994;48:339-344.
23. Conger JD, Falk SA: Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977;59:786-793.
24. Homsi E, Barreiro MF, Orlando JM, Higa EM: Prophylaxis of acute renal failure in patients with rhabdomyolysis. Renal Fail 1997;19:283-288.
25. Sward K, Valson F, Ricksten SE: Long term infusion of atrial natriuretic peptide (ANP) improves renal blood flows and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand 2001;45:536-542.
26. Conger JD: Acute uric acid nephropathy. Semin Nephrol 1981;1:69-74.
27. Kursh ED, Resnick MI: Dissolution of uric acid calculi with systemic alkalization. J Urol 1984;132:286-287.
28. Morley CJ, Houston IB, Morris-Jones P: Acute renal failure and gout as presenting features of acute lymphoblastic leukemia. Arch Dis Child 1976;51:723-725.
29. Stark ME, Dyer MC, Coonley CJ: Fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer 1987;60:762-764.
30. Hsu HH, Chan YL, Hung CC: Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure; clinical feature and therapeutic approach. J Nephrol 2004;17:50-56.
31. Bunchman TE, Gale GB, O'Connor DM, Salinas-Madrigal L, Chu JY: Renal biopsy diagnosis of acute lymphocytic leukemia. Clin Nephrol 1992;38:142-144.
32. Larsen G, Loghman-Adham M: Acute renal failure with hyperuricemia as initial presentation of leukemia in children. J Pediatr Hematol Oncol 1996;18:191-194.
33. Jasek AM, Day HJ: Acute spontaneous tumor lysis syndrome. Am J Hematol 1994;47:129-131.
34. Lotfi M, Brandwein JM: Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature. Leuk Lymphoma 1998:29:625-628.
35. Sile S, Wall BM: Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis. Am J Kidney Dis 2001;38:E21.
36. DeConti RC, Calabresi P: Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic diseases. N Engl J Med 1966;274:481-486.
37. Feusner J, Farber MS: Role of intravenous allopurinol in the management of acute tumor lysis syndrome. Semin Oncol 2001;28(suppl 5):13-18.
38. Spector T: Inhibition of urate production by allopurinol. Biochem Pharmacol 1977:26:355-358.
39. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Beanerjee TK, et al: Xanthine neplrropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970;283:354-357.
40. Potter JL, Silvidi AA: Xanthine lithiasis, nephrocalcinosis and renal failure in patients treated with allopurinol. Clin Chem 1987;33:2314-2316.
41. Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE: Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972;21:771-778.
42. Elion GB, Benezra FM, Beardmore TD, et al: Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol 1980;263-267.
43. Elitek (Rasburicase) prescribing information. New York, Sanofi-Synthelabo, July 2002.
44. Pui CH: Rasburicase, a potent uricolytic agent. Expert Opin Pharmacother 2002;3:433-452.
45. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
46. Pui CH, Jeha S, Irwin D, Camitta B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: Results of a compassionate-use trial. Leukemia 2001;15:1505-1509.
47. Pui CH, Relling MV Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-1816.
48. Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F: Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998;77:18-20.
49. Massera G, Jankovic M, Zurlo MG, et al: Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982;100:152-155.
50. Goldman S, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
51. Goldman SC: Rasburicase: Potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003;3:429-433.
52. Agha-Razii M, Amyot SL, Pichette V, Cardinal J, Ouimet D, Leblanc M: Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 2000;54:59-63.
53. Pichette V, Leblanc M, Bonnardeaux A, Ouimet D, Geadeh D, Cardinal J: High dialysate flow rate continuous arterio venous hemodialysis: A new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994;23:591-596.
54. Mehta RL, Pascual MT, Soroko S, Chertow GM, the PICARD study group: Diuretics, mortality and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547-2553.
55. Rigas DA, Duerst ML, Jump ME, Odgood EE: The nucleic acids and other phosphorous compounds of human leukemic leukocytes: Relation to cell maturity. J Lab Clin Med 1956;48:356.
56. Zager RA, et al: Hyperphospatemia: A factor that provokes severe experimental acute renal failure. J Lab Clin Med 1982;100:230-239.
57. Lau K: Phosphate excess and progressive renal failure: The precipitation-calcification hypothesis. Kidney Intern 1989;36:918-937.
58. Dobyan DC, et al: The role of phosphate in the potentiation or amelioration of acute renal failure. Miner Electrolyte Metab 1991;17:112-115.
59. Van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: Risks of alkalinisation. Ann Oncol 2004;15:175-176.
60. Herbert LA, Leman J, Peterson JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers calcium concentration. J Clin Invest 1966;45:1886-1894.
61. Haas M, Ohler L, Watzke H, Bohmig G, Prokesch R, Druml W: The spectrum of acute renal failure in tumour lysis syndrome. Nephrol Dial Transplant 1999;14:776-779.
62. Dutel JL, et al: Insuffisance rénale aigue anurique par hyperphosphorémie au cours des leucemies aigues lymphoblastiques. Rev Med Interne 1983;3:284-288.
63. Zusman J, et al: Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973;289:1335-1340.
64. Kjellstrand CM, Campbell DC, Von Hartitzsch B, Buselmeier TJ: Hyperuricemic acute renal failure. Arch Intern Med 1974;133:349-359.
65. Wechsler DS, Kastan MB, Fivush BA: Resolution of nephrocalcinosis associated with tumor lysis syndrome. Pediatr Hematol Oncol 1994;11:115-118.
66. Farber MS: Pharmacoeconomic considerations in the management of acute tumor lysis syndrome. Semin Oncol 2001;28(suppl 5):19-22.
67. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A: Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003;44:77-83.